Acute myeloid leukemia: introduction to a series highlighting progress and ongoing challenges

Richard F Schlenk

DOI: https://doi.org/10.3324/haematol.2022.280803

2023-02-02

Haematologica

Abstract:Acute myeloid leukemia (AML) is the most common acute leukemia in adults and its incidence increases with higher age. Currently, the median age at diagnosis in western countries ranges between 65 to 72 years; in consequence half of the patients with newly diagnosed AML are older than this median and are septua-, octo- or nonagenarians. In the era in which cytostatic chemotherapy, autologous as well as allogeneic hematopoietic cell transplantation were the main pillars of curative treatment approaches, significant improvements in outcome were predominantly restricted to "younger" patients, meaning adult patients younger than 60 years. 1 With the advent of hypomethylating agents, 2 , 3 a treatment strategy with generally mild side effects and good tolerability became available for older patients, even allowing outpatient administration. Furthermore, hypomethylating agents yielded a small but significant improvement in outcome. 2 , 3 However, the long-term outcome beyond 2 years was still dismal and not improved by these agents. 2 , 3 This situation changed meaningfully in 2020 with the introduction of the BCL-2-inhibitor venetoclax in combination with hypomethylating agents. 4 For the first time a substantial proportion of older patients achieved a complete remission either with full or incomplete blood count recovery and, even more importantly, a favorable long-term outcome. 4 Since then, successful treatment and long-term remissions are possible even in octa- and nonagenarians. 5 , 6 In my own outpatient clinic, it is amazing to see an increasing proportion of septua- and octogenarians for regular 3-monthly follow-up visits in long-term remission after treatment with azacitidine/venetoclax.

hematology